Non-alcoholic steatohepatitis (NASH) is a widespread disease affecting up to ~12% of the US population – characterized by lipid accumulation in hepatocytes, infiltration of immune cells and fibrosis ...

The drug, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, did not meet the primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH in the STELLAR-4 ...

Liver biopsy and noninvasive markers should be used to stage and grade nonalcoholic ... gold standard for diagnosis of NASH and staging of fibrosis is essential but not sufficient.

In the study, PPAR agonist elafibranor was unable to hit the primary objective of resolving NASH without worsening fibrosis (scarring ... have failed in the latter stages of clinical testing.

“While the study was not designed to be statistically powered to evaluate improvement in fibrosis ... a mid-stage trial for a liver disorder known as nonalcoholic steatohepatitis (NASH ...

Weight loss drug developer Viking Therapeutics (NASDAQ:VKTX) traded higher premarket Tuesday after announcing 52-week data from a mid-stage ... in fibrosis with no worsening of NASH, compared ...

Several studies have reported changes in hepatic histology from liver biopsies obtained at the time of bariatric surgery and after weight loss ( Table 1). Previous reviews [19,75–77] have ...

On the secondary endpoint of NASH resolution with no worsening of fibrosis, VK2809-treated patients demonstrated NASH resolution ranging from 63% to 75%, compared with 29% for placebo. Across the ...

placebo). Improvement in fibrosis without worsening of NASH was defined as a ≥1-stage improvement in fibrosis and no increase in NAS for ballooning, inflammation, or steatosis. On the ...

VK2809 achieved a liver fat reduction of 37%-55% and ≥30% fat reduction for 64%-88% of patients at 52 weeks. NASH resolution rates were 63%-75%, and fibrosis ...